First Gene Therapy for Muscular Dystrophy Costs $3.2 Million

The first gene therapy for muscular dystrophy, developed by Sarepta Therapeutics, has been approved by the FDA with a price tag of $3.2 million per patient. The therapy, called SRP-9001, is a one-time treatment for a rare genetic disease that causes muscle weakness and wasting. The high cost has sparked controversy and raised concerns about access to life-saving treatments for rare diseases.